News
Complete Genomics Announces Commercial Partnership with Human Cell Atlas to Offer its Members Stereo-seq Spatial Transcriptomics at NextGen Omics & Spatial Biology Conference
SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, announced at the NextGen Omics & Spatial Biology Conference that it has entered a commercial partnership with Human Cell Atlas (HCA) to offer its STOmics spatial transcriptomics products to HCA members. Human Cell Atlas (HCA), an international collaborative research consortium, is mapping all cell types in the healthy body, across time from development to adulthood. This...
Complete Genomics Announces Partnership with BioTuring and the Go Optical STOmics microscope.
SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, announced at the NextGen Omics & Spatial Biology Conference that it has partnered with BioTuring, developer of advanced bioinformatics algorithms and software that enables rapid OMICS analysis, to offer researchers access to SpatialX, a powerful deep-learning tool for unified multi-technology spatial data analysis compatible with STOmics chemistries designed to analyze spatial...
Complete Genomics Highlights Clinical Research Sequencing Solutions and Partnerships at AMP 2025
BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing technologies, will showcase its expanded portfolio for oncology and infectious disease research at the 2025 Association for Molecular Pathology (AMP) Annual Meeting, Nov. 11-15 in Boston. Located at Booth 1210 at AMP, Complete Genomics will highlight its DNBSEQ sequencing platforms and collaborations with leading assay developers and clinical laboratories, underscoring how its technology...
Complete Genomics Highlights New Products, Partnerships, First DNBSEQ User Group Meeting at ASHG 2025
BOSTON, Oct. 14, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a series of milestones at the American Society of Human Genetics (ASHG) Annual Meeting, Oct. 14-18, 2025 in Boston. At ASHG 2025, for the first time, Complete Genomics will host a DNBSEQ(TM) User Group Meeting to bring together researchers and customers to share best practices, explore applications across oncology, rare disease and population genomics, and hear updates from the...
Complete Genomics Names Four Winners of Spatial Xcellerator Grant Program
SAN JOSE, Calif., April 15, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced four winners from 30 applicants to its Spatial Xcellerator Grant Program. Winning projects address oncology, pediatric brain tumors, spinal cord injury and Alzheimer's disease. As the exclusive U.S. distributor of STOmics' Stereo-seq technology for spatial transcriptomics, Complete Genomics launched the Spatial Xcellerator Grant Program and spatial certified service...
Complete Genomics and SOPHiA GENETICS Announce Integration of MSK-IMPACT® and MSK-ACCESS® Assays on DNBSEQ-T1+ Platform at AMP 2025
BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS(R) and MSK-IMPACT(R) powered with SOPHiA DDM(TM) on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to...
Complete Genomics announces Gene by Gene as its newest sequencing service provider at ASHG
BOSTON, Oct. 13, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced at the American Society of Human Genetics Annual Meeting that it has added Houston-based Gene by Gene, a leading genetics laboratory, to its Sequencing Service Provider Program. The Complete Genomics Service Provider Program connects its customers to a network of service providers, offering access to high-quality sequencing services using Complete Genomics DNBSEQ(TM) sequencing...
Complete Genomics unveils DNBSEQ-T1+ and DNBSEQ-E25 Flash at AGBT 2025 General Meeting
MARCO ISLAND, Fla., Feb. 24, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today unveiled its latest high-performance sequencing solutions at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting. The newly introduced DNBSEQ-T1+* and DNBSEQ-E25 Flash* are designed to deliver speed, flexibility, and efficiency, empowering researchers with faster, high-quality genomic data. DNBSEQ-T1+: Mid-Throughput Sequencing with Industry-Leading Speed...
Complete Genomics, Velsera partner to integrate sequencing and analysis platforms
CHICAGO, April 28, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing announced a collaboration with Velsera, a leading global healthcare technology company, to deliver an end-to-end genetic testing solution that integrates DNBSEQ(TM) sequencing technology with Velsera's Clinical Genomics Workspace (CGW) data analysis solution. The partnership, announced this week at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, will accelerate...
In 2024, Complete Genomics expanded U.S. manufacturing and technology capabilities toward a diversified, reliable supply chain for its flexible and cost-effective NGS solutions
SAN JOSE, Calif., Jan. 9, 2025 /PRNewswire/ -- In 2024, Complete Genomics, a pioneering genomic sequencing company, expanded its U.S. manufacturing footprint with augmented technology capabilities to diversify its supply chain helping it to continue reliably serving customers with flexible, cost-effective next generation sequencing (NGS) solutions. Expanding U.S. manufacturing capabilities in 2024 and beyond After weathering a year of geopolitical conflict which resulted in the failure of the...
SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine
BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS(R) and MSK-IMPACT(R) powered with SOPHiA DDM(TM) on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to...